Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 70, Issue 4 , Pages 383-390 , April 2004

Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum

  • A.J Richardson

      Affiliations

    • Corresponding Author InformationTel.: +44-1865-513433; fax: +44-1865-438304
    • Financial support for Dr. Richardson's work is currently provided by three UK charities: Mansfield College, Oxford; the Dyslexia Research Trust; and Food and Behaviour Research.

,Accepted 18 December 2003.

References 

  1. Richardson AJ, Ross MA. Fatty acid metabolism in neurodevelopmental disorder (a new perspective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum). Prostaglandius Leukot Essent Fatty Acids. 2000;63(1–2):1–9
  2. Stevens LJ, et al.  Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am. J. Clin. Nutr. 1995;62(4):761–768
  3. Stevens LJ, et al.  Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiol. Behav. 1996;59(4–5):915–920
  4. Taylor KE, et al.  Dyslexia in adults is associated with clinical signs of fatty acid deficiency. Prostaglandius Leukot Essent Fatty Acids. 2000;63(1–2):75–78
  5. J.G. Bell, et al., Apparent fatty acid deficiency in autistic spectrum disorders, Prostaglandius Leukot Essent Fatty Acids, 2004, in press.
  6. Mitchell EA, et al.  Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin. Pediatr. Phila. 1987;26(8):406–411
  7. Vancassel S, et al.  Plasma fatty acid levels in autistic children. Prostaglandius Leukot Essent Fatty Acids. 2001;65(1):1–7
  8. Richardson AJ, et al.  Abnormal cerebral phospholipid metabolism in dyslexia indicated by phosphorus-31 magnetic resonance spectroscopy. NMR Biomed. 1997;10(7):309–314
  9. MacDonell LE, et al.  Increased levels of cytosolic phospholipase A2 in dyslexics. Prostaglandius Leukot Essent Fatty Acids. 2000;63(1–2):37–39
  10. Colquhoun I, Bunday S. Alack of essential fatty acids as a possible cause of hyperactivity in children. Med. Hypotheses. 1981;7(5):673–679
  11. Stordy BJ. Benefit of docosahexaenoic acid supplements to dark adaptation in dyslexics. Lancet. 1995;346(8971):385
  12. Stordy BJ. Dark adaptation, motor skills, docosahexaenoic acid, and dyslexia. Am. J. Clin. Nutr. 2000;71(1 Suppl):323S–326S
  13. Bell JG, et al.  Red blood cell fatty acid compositions in a patient with autistic spectrum disorder (a characteristic abnormality in neurodevelopmental disorders?). Prostaglandius Leukot Essent Fatty Acids. 2000;63(1–2):21–25
  14. Slade M, Priebe S. Are randomised controlled trials the only gold that glitters?. Br. J. Psychiatry. 2001;179:286–287
  15. Aman MG, Mitchell EA, Turbott SH. The effects of essential fatty acid supplementation by Efamol in hyperactive children. J. Abnorm. Child Psychol. 1987;15(1):75–90
  16. Arnold LE, et al.  Gamma-linolenic acid for attention-deficit hyperactivity disorder (placebo-controlled comparison to d-amphetamine). Biol. Psychiatry. 1989;25(2):222–228
  17. Bourre JM, et al.  Brain cell and tissue recovery in rats made deficient in n-3 fatty acids by alteration of dietary fat. J. Nutr. 1989;119(1):15–22
  18. Arnold LE, Pinkham SM, Votolato N. Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder?. J. Child Adolesc. Psychopharmacol. 2000;10(2):111–117
  19. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother. 2002;56(8):365–379
  20. J.R. Burgess, Attention deficit hyperactivity disorder: observational and interventional studies, in: NIH Workshop on Omega-3 Essential Fatty Acids and Psychiatric Disorders. National Institutes of Health, Bethesda, 1998.
  21. Stevens L, et al.  EFA supplementation in children with inattention, hyperactivity and other disruptive behaviours. Lipids. 2003;38(10):1007–1021
  22. Voigt RG, et al.  A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J. Pediatr. 2001;139(2):189–196
  23. Peet M, et al.  Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 2001;49(3):243–251
  24. Marangell LB, et al.  A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am. J. Psychiatry. 2003;160(5):996–998
  25. Kadesjo B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J. Child Psychol. Psychiatry. 2001;42(4):487–492
  26. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry. 2002;159(3):477–479
  27. Peet M, Horrobin DF. Adose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry. 2002;59(10):913–919
  28. Stoll AL, et al.  Omega 3 fatty acids in bipolar disorder (a preliminary double-blind, placebo-controlled trial). Arch. Gen. Psychiatry. 1999;56(5):407–412
  29. S. Hirayama, T. Hamazaki, K. Terasawa, The Effect of Foods Containing DHA on Symptoms of Attention-deficit Hyperactivity Disorder: A Randomised Controlled Trial, ISSFAL Meeting, Montreal, 2002.
  30. Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2002;26(2):233–239
  31. Conners CK. Conners’ Parent Rating Scales—Revised. New York: Multi-Health Systems Inc; 1997;
  32. Richardson AJ. Clinical trials of fatty acid supplementation in Dyslexia and Dyspraxia. In:  Peet M, G.I ,  Horrobin DF editor. Phospholipid Spectrum Disorders in Psychiatry and Neurology. Carnforth: Marius Press; 2003;p. 491–500
  33. In:  Peet M,  Glen I,  Horrobin DF editor. Phospholipid Spectrum Disorders in Psychiatry and Neurology. 2nd Edition. Carnforth: Marius Press; 2003;
  34. Peet M, Horrobin DF. E-E-Multicentre-Study-Group, A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatry Res. 2002;36(1):7–18
  35. Su KP, et al.  Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 2003;13(4):267–271
  36. Puri BK, Richardson AJ. The effects of olive oil on omega3 fatty acids and mood disorders. Arch. Gen. Psychiatry. 2000;57(7):715
  37. Sugiura T, et al.  Enzymatic synthesis of oleamide (cis-9, 10-octadecenoamide), an endogenous sleep-inducing lipid, by rat brain microsomes. Biochem. Mol. Biol. Int. 1996;40(5):931–938
  38. Cravatt BF, et al.  Chemical characterization of a family of brain lipids that induce sleep. Science. 1995;268(5216):1506–1509
  39. Boger DL, Henriksen SJ, Cravatt BF. Oleamide (an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules). Curr. Pharm. Des. 1998;4(4):303–314
  40. Huitron-Resendiz S, et al.  Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity in rats. Exp. Neurol. 2001;172(1):235–243
  41. Fedorova I, et al.  Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J. Pharmacol. Exp. Ther. 2001;299(1):332–342

PII: S0952-3278(04)00010-9

doi: 10.1016/j.plefa.2003.12.020

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 70, Issue 4 , Pages 383-390 , April 2004

Article Tools